Stay updated with breaking news from Nasdaq Blph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock. Bellerophon Therapeutics Price Performance Shares of BLPH stock opened at $7.46 on Wednesday. The business’s fifty day moving average price is $3.68 and its […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 945,100 shares, an increase of 473.8% from the February 28th total of 164,700 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is […]
StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock. Bellerophon Therapeutics Price Performance BLPH opened at $7.87 on Tuesday. The stock has a market cap of $76.58 million, a P/E ratio of -3.94 and […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 12,500 shares, a drop of 53.0% from the May 31st total of 26,600 shares. Based on an average trading volume of 57,700 shares, the days-to-cover ratio is […]
Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and […]